AXL receptor tyrosine kinase as a therapeutic target in NSCLC

Ross A Okimoto,1 Trever G Bivona1,2 1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA Abstract: The AXL receptor tyrosine kina...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Okimoto RA, Bivona TG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/66beb47003984936bec97fbf70841834
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66beb47003984936bec97fbf70841834
record_format	dspace
spelling	oai:doaj.org-article:66beb47003984936bec97fbf708418342021-12-02T05:25:18ZAXL receptor tyrosine kinase as a therapeutic target in NSCLC1179-2728https://doaj.org/article/66beb47003984936bec97fbf708418342015-04-01T00:00:00Zhttp://www.dovepress.com/axl-receptor-tyrosine-kinase-as-a-therapeutic-target-in-nsclc-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Ross A Okimoto,1 Trever G Bivona1,2 1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA Abstract: The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial–mesenchymal transition-associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models. These findings implicate AXL as a promising therapeutic target in lung cancer. In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics. Keywords: Gas6, lung cancer, targeted therapy, drug resistance Okimoto RABivona TGDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 27-34 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Okimoto RA Bivona TG AXL receptor tyrosine kinase as a therapeutic target in NSCLC
description	Ross A Okimoto,1 Trever G Bivona1,2 1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA Abstract: The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial–mesenchymal transition-associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models. These findings implicate AXL as a promising therapeutic target in lung cancer. In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics. Keywords: Gas6, lung cancer, targeted therapy, drug resistance
format	article
author	Okimoto RA Bivona TG
author_facet	Okimoto RA Bivona TG
author_sort	Okimoto RA
title	AXL receptor tyrosine kinase as a therapeutic target in NSCLC
title_short	AXL receptor tyrosine kinase as a therapeutic target in NSCLC
title_full	AXL receptor tyrosine kinase as a therapeutic target in NSCLC
title_fullStr	AXL receptor tyrosine kinase as a therapeutic target in NSCLC
title_full_unstemmed	AXL receptor tyrosine kinase as a therapeutic target in NSCLC
title_sort	axl receptor tyrosine kinase as a therapeutic target in nsclc
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/66beb47003984936bec97fbf70841834
work_keys_str_mv	AT okimotora axlreceptortyrosinekinaseasatherapeutictargetinnsclc AT bivonatg axlreceptortyrosinekinaseasatherapeutictargetinnsclc
_version_	1718400415608864768

AXL receptor tyrosine kinase as a therapeutic target in NSCLC

Ejemplares similares